All the news Showing 10 of 83 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Curing hepatitis C with DAAs linked to 71% reduction in liver cancer Liz Highleyman / 30 October 2017 People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, ... Rapid fibrosis progression in large proportion of HIV-positive gay men after acute HCV Michael Carter / 11 October 2017 Over a third of HIV-positive gay men develop significant liver fibrosis after an episode of acute hepatitis C virus (HCV) infection, German investigators report in the Journal of Viral Hepatitis. ... Cenicriviroc may reduce fibrosis in people with fatty liver disease Liz Highleyman / 05 October 2017 Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, was associated with a decrease in liver fibrosis in people with non-alcoholic steatosis, a type of fatty ... Drinking three or more cups of coffee a day halves the risk of dying for people with HIV/HCV co-infection Michael Carter / 03 October 2017 Drinking three or more cups of coffee a day halves the risk of death from any cause for people with HIV/hepatitis C virus (HCV) co-infection, French investigators report in the ... Liver fibrosis speeds up around the menopause in women with HIV and HCV co-infection Michael Carter / 22 August 2017 Menopause is associated with accelerated liver fibrosis in women with HIV and hepatitis C virus (HCV) co-infection, investigators from the United States report in the online edition of Clinical Infectious Diseases. The study showed ... People with HIV are at risk for liver fibrosis and steatosis Michael Carter / 21 August 2017 Metabolic syndrome, type 2 diabetes and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with HIV, including those who do ... Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV Michael Carter / 17 August 2017 Switching to raltegravir from efavirenz is associated with significant improvements in liver steatosis for HIV-positive people with non-alcoholic fatty liver disease, Spanish investigators report in the online edition of Clinical ... Albumin reduces complications and improves survival in people with decompensated cirrhosis Liz Highleyman / 08 May 2017 Long-term administration of human albumin was associated with fewer serious complications, less hospitalisation, better quality of life and longer survival for people with decompensated liver cirrhosis, according to a report at the International ... Nivolumab increases survival for people with advanced liver cancer Liz Highleyman / 22 April 2017 The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well tolerated as a treatment for advanced liver cancer that did not respond to standard treatment, researchers reported on ... Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies Liz Highleyman / 21 April 2017 People with hepatitis C who take treatment with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher ... ← Prev12345...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive